Standard pathological assessment also includes immunohistochemistry ... of adrenocortical carcinoma. 69,112–114 There is increasing evidence that there are probably three molecular subtypes bearing ...

Fruzaqla given in combination with sintilimab slowed progression in the second line for those with locally advanced or metastatic renal cell carcinoma.

What Is Renal Cell Carcinoma? It's the most common type of kidney cancer. Although it’s a serious disease, finding and treating it early makes it more likely that you’ll be cured. No matter ...

mRCC, metastatic renal cell carcinoma; OS, overall survival; PFS, progression-free survival. Primary insurance status was categorized into three groups—patients with Medicare, private insurance, and ...

When renal cell cancer is “metastatic,” that means it has spread from your kidney to other parts of your body. Bones are a common place for this cancer to travel. It's harder to treat the ...

PSMA may be a noninvasive biomarker for predicting treatment response in metastatic clear cell renal cell carcinoma (RCC).

A research team led by Prof. Sun Cheng from the University of Science and Technology of China (USTC), in collaboration with ...

The cohort had a median age of 65 years (IQR 53–68), with 74% male and 82% Caucasian. Of the total 808 gene panel, 15 genes were mutated by >5% in the entire cohort, with PBRM1, SETD2, KDM5C, TP53, ...

March 10, 2025--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has ... to early-stage non-small cell lung cancer (NSCLC) and previously ...

SAN FRANCISCO and SUZHOU, China, March 23, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that ...